Spruce Point Capital is short Bunge Global SA (NYSE: BG), an S&P 500 global agribusiness, and calls for an independent investigation into the accuracy of its financial reporting and accounting. Spruce Point views Bunge as a complex and troubled roll-up that has demonstrated an inability to deliver value to shareholders absent external financing — since 1999, it has generated a cash flow deficit of -$1.6bn after capex while making +$4.7bn in dividends and +$3.9bn in buybacks effectively through debt-financing. The $10.6bn Viterra acquisition from Glencore is viewed as a deal borne out of necessity to deflect from core oilseeds challenges, and has wildly disappointed. Spruce Point estimates 55-80% downside risk and warns of extreme insider selling of up to 30% of the stock.
We did not write this report. We catalogued it. The underlying research was published by Spruce Point Capital. The Forensic Ledger does not endorse its conclusions. Always read the original document.
The Core Allegation
Bunge Global SA (NYSE: BG) is a complex and troubled roll-up that has demonstrated an inability to deliver value to shareholders absent external financing. Spruce Point calls for an independent investigation into the accuracy of its financial reporting and accounting.
Debt-Financed Shareholder Returns
Since 1999, Bunge has:
- Generated a cash flow deficit of -$1.6 billion after capital expenditures, business investment, and asset-shuffling and repositioning
- Made +$4.7 billion in dividends and +$3.9 billion in share repurchases
- These returns were effectively through debt-financing — not organic cash generation
Core Oilseeds Decline
Bunge is under core pressure in oilseeds, once its highest EBIT contributor and which it once claimed was a global leading business and difficult to replicate.
The Viterra Acquisition Deflection
The $10.6 billion Viterra acquisition from Glencore (LSE: GLEN), announced June 2023:
- Spruce Point views it as a deal borne out of necessity to deflect from core challenges
- It has wildly disappointed
- Used to mask the deterioration in the oilseeds business
The GLP-1 Risk
Bunge says nothing about the growing impact of GLP-1 weight loss drugs in its SEC filings or conference calls. However, with customers in the food products industry, Spruce Point believes Bunge is likely feeling the effects of reduced food demand from weight-loss drug adoption.
Accounting and Disclosure Concerns
Bunge claims to be committed to transparency. Spruce Point believes the Board should:
- Investigate financial disclosure practices
- Provide more clarity around its financial reporting
The Downside
Spruce Point estimates:
- 55% – 80% potential downside
- Material market underperformance risk
- New 2030 EPS guidance should be discounted
- Share price is a poor risk/reward
Impending Insider Selling
Extreme insider selling of up to 30% of the stock may be on the near-term horizon — a major red flag for a company already under financial pressure.
subsequent events
- 1999-2026Bunge generates -$1.6bn cash flow deficit while paying $8.6bn in dividends and buybacks via debt
“Demonstrated an inability to deliver value to shareholders absent external financing”
- 2023-06Bunge announces $10.6bn Viterra acquisition from Glencore
“A deal borne out of necessity to deflect from its core challenges”
- 2026-03-25Spruce Point publishes short report on Bunge
“We estimate 55% - 80% potential downside and material market underperformance risk”
Source — https://www.sprucepointcap.com/research/bunge-global-sa
Not investment advice. This dossier summarizes a third-party short report. The Forensic Ledger did not produce the underlying research and does not endorse its conclusions. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.